Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis

Ads

You May Also Like

BriaCell Update:  Early Evidence of Efficacy and Safety of Bria-IMT™

BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics ...

scPharmaceuticals Announces Appointment of Two New Directors

BURLINGTON, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company ...

Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA

SAINT-GENIS-POUILLY, France, July 27, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA ...